BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 23297042)

  • 41. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer--clinical examination, mammography, or magnetic resonance imaging?
    Wright FC; Zubovits J; Gardner S; Fitzgerald B; Clemons M; Quan ML; Causer P
    J Surg Oncol; 2010 Jun; 101(7):604-10. PubMed ID: 20461768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
    Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
    J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI.
    Balu-Maestro C; Chapellier C; Bleuse A; Chanalet I; Chauvel C; Largillier R
    Breast Cancer Res Treat; 2002 Mar; 72(2):145-52. PubMed ID: 12038705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.
    Takeda K; Kanao S; Okada T; Kataoka M; Ueno T; Toi M; Ishiguro H; Mikami Y; Togashi K
    Eur J Radiol; 2012 Oct; 81(10):2627-31. PubMed ID: 22221829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis.
    Yuan Y; Chen XS; Liu SY; Shen KW
    AJR Am J Roentgenol; 2010 Jul; 195(1):260-8. PubMed ID: 20566826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization.
    Wallace AM; Daniel BL; Jeffrey SS; Birdwell RL; Nowels KW; Dirbas FM; Schraedley-Desmond P; Ikeda DM
    J Am Coll Surg; 2005 Apr; 200(4):527-37. PubMed ID: 15804466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
    Lehman CD; Blume JD; Weatherall P; Thickman D; Hylton N; Warner E; Pisano E; Schnitt SJ; Gatsonis C; Schnall M; DeAngelis GA; Stomper P; Rosen EL; O'Loughlin M; Harms S; Bluemke DA;
    Cancer; 2005 May; 103(9):1898-905. PubMed ID: 15800894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
    Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
    Williams M; Eatrides J; Kim J; Talwar H; Esposito N; Szabunio M; Ismail-Khan R; Kiluk J; Lee M; Laronga C; Khakpour N
    Am J Surg; 2013 Oct; 206(4):567-73. PubMed ID: 23809673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusion of magnetic resonance and scintimammography images for breast cancer evaluation: a pilot study.
    Duarte GM; Cabello C; Torresan RZ; Alvarenga M; Telles GH; Bianchessi ST; Caserta N; Segala SR; de Lima Mda C; Etchebehere EC; Camargo EE; Tinois E
    Ann Surg Oncol; 2007 Oct; 14(10):2903-10. PubMed ID: 17632758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic accuracy of mammography, ultrasonography and magnetic resonance imaging in the detection of intraductal spread of breast cancer following neoadjuvant chemotherapy.
    Kubota K; Ogawa Y; Nishioka A; Kariya S; Itoh S; Murata Y; Hamada N; Maeda H; Tanaka Y
    Oncol Rep; 2007 Apr; 17(4):915-8. PubMed ID: 17342336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.